ZYTOPROTEC AT A GLANCE
Our mission is to make a novel therapeutic approach a reality in PD – an area where clinicians and patients saw disappointingly little innovation in decades.
Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial in 2022.
The Company is lead by a management team that combines extensive expertise in the renal business, in financing and Venture Capital, as well as in nephrology and clinical development.
MANAGEMENT
- With Zytoprotec since 2015
- Managing Director since November 2015
Prior Experience:
- Joined as Managing Director in November 2015
- Over 20 years experience in the hospital and renal business acting in various management capacities
- In 1997, he sold InfusMedizintechnikas its Managing Director to Baxter
- Occupied several functions within Baxter thereafter, most recently General Manager for Baxter and Gambro-Renal, Austria
- Co-founder of Zytoprotec
- Chief Scientific Officer
Prior Experience:
- Professor of pediatric nephrology and gastroenterology at Medical University of Vienna and Head of division pediatric nephrology and gastroenterology at the department of pediatrics and adolescent medicine
- Has conducted research at Yale and UCLA and teaches medicine at Medical University of Vienna
- Author of more than 100 scientific articles in journals and books and regular speaker at dialysis
- With Zytoprotec since 2014
Prior Experience:
- Over 20 years of expertise in biotech-related venture capital
- Between 1993-2010, general partner and CFO of TVM Capital, a European venture firm
- Managed and structured more than 100 transactions at TVM, including financings, acquisitions and IPOs
Head of Research
Key Milestones
2019 Participation in EU Horizon 2020 project Improve-PD
2017 FDA grants Orphan Drug Designation to PDprotec®
2017 Results of Phase II trial of PDprotec®: Outstanding safety and efficacy profile
2016/17 Series A2 Financing
2016 Zytoprotec opens laboratory for biomarker research in PD
2015 Double-blinded, placebo-controlled Phase II trial of PDprotec® initiated
2013 Series A Financing
2012 EPO grants patent for PDprotec®
2012 Phase I/II trial with PDprotec® completed
2011 First financing with private investors
2007 Zytoprotec founded
PARTNERS & COOPERATIONS
